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journal.publications.chestneBACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension
(PAH) is often limited by patient/physician dissatisfaction with the delivery methods.
Complications associated with external pump-delivered continuous therapy include IV
catheter-related bloodstream infections and subcutaneous infusion site pain. We therefore
investigated a fully implantable intravascular delivery system for treprostinil infusion.
METHODS: Amulticenter, prospective, single-arm, clinical trial (DelIVery for Pulmonary Arterial
Hypertension) was conducted by using an implantable intravascular delivery system. The
implanted pumpswere reﬁlled percutaneously at least every 12weeks. The primary end point was
the rate of catheter-related complications using the new model 10642 catheter compared with a
predeﬁned objective performance criterion of 2.5 per 1,000 patient-days based on the literature.
RESULTS: Patients (n ¼ 60) with severe PAH (World Health Organization group 1) receiving
a stable dose of IV treprostinil for at least 4 weeks received an implant device and were
followed up for 12.1  4.4 months. Six catheter-related complications occurred, corre-
sponding to a complication rate of 0.27 per 1,000 patient-days. The 97.5% upper one-sided
conﬁdence bound of 0.59 was less than the predeﬁned criterion of 2.5 per 1,000 patient-days
(P < .0001). Plasma treprostinil levels at 1 week postimplantation were highly correlated with
baseline levels (r ¼ 0.91; P < .0001). The delivery system management time as reported
by the patients was 2.5  1.7 hours per week preimplantation, and this time decreased to
0.6  0.8 hour per week at 6 months’ postimplantation (P < .0001). All patients rated overall
satisfaction with the implantable system as good, very good, or excellent at 6 weeks and
6 months. There were no catheter-related bloodstream infections or catheter occlusions.
CONCLUSIONS: The implantable intravascular delivery system delivered treprostinil to patients
with PAHwith a low rate of catheter-related complications and a high rate of patient satisfaction.
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The development of targeted therapies for pulmonary
arterial hypertension (PAH) has led to improved
symptoms and outcomes.1,2 Parenterally administered
prostanoids are indicated in advanced PAH; however,
prostanoid therapy is underused due to reluctance from
patients and physicians. In a report by Farber et al,3
61% of patients with PAH whose condition deteriorated
to New York Heart Association (NYHA) functional class
IV were not receiving parenteral prostanoid therapy
90 days after their deterioration, despite an indication
for this therapy based on guideline recommendations.
In addition, indwelling central venous catheters increase
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28 Original ResearchSubcutaneous administration is associated with
signiﬁcant infusion site pain, which may preclude
continued administration.
Limitations with current prostanoid delivery systems
prompted a clinical trial (DelIVery for Pulmonary
Arterial Hypertension) to determine if a fully
implantable, programmable delivery system could
safely administer treprostinil (Remodulin, United
Therapeutics Corporation) to patients with PAH.
Treprostinil was chosen because it is stable at body
temperature5 and has a longer plasma half-life (w4 h6)
than epoprostenol.Patients and Methods
DelIVery for Pulmonary Arterial Hypertension was a multicenter,
prospective, single-arm clinical trial using an investigational implantable
drug delivery system conducted at 10 US centers. The implantable drug
delivery system consisted of the model 10642 Implantable Intravascular
Catheter,5 the model 8637 SynchroMed II implantable drug delivery
pump, and the model 8840 N’Vision programmer (Medtronic, Inc).
A key design intent of the model 10642 catheter was to prevent
occlusion while delivering treprostinil at low ﬂow rates.
Patients
Patients included in this trial had stable PAH (Word Health
Organization group 1)7 and were receiving continuous IV infusion of
treprostinil by using an external infusion pump. Eleven patients
(18%) were prescribed subcutaneous treprostinil within 3 months
of pump implantation and were switched to IV treprostinil
41  12 days (range, 30 to 71 days) prior to implantation. All
patients were in stable condition, deﬁned as NYHA functional class
I, II, or III with no change in treprostinil dose for at least 4 weeksand no additional PAH treatment for at least 2 months before
enrollment. The exclusion criteria included: age < 18 years; NYHA
functional class IV; a recent (within 3 months) infection; unresolved
infection; increased susceptibility to infection; chronic renal disease;
an implanted pacemaker, implantable cardioverter-deﬁbrillator, or
spinal cord stimulator; or an existing external catheter that would
remain in place after implantation of the system. Patients were also
excluded if their body habitus was unacceptable for an 80-cm
catheter or abdominal subcutaneous pump implantation.
This study was conducted in accordance with the amended Declaration
of Helsinki. The institutional review boards at each center approved
the protocol, and written informed consent was obtained from all
patients (e-Table 1).
Study End Points
The primary end point was the rate of catheter-related complications per
1,000 patient-days using the implantable system compared with an
objective performance criterion (OPC) of 2.5 complications per
1,000 patient-days. A complication was an adverse event that required an
invasive intervention (e-Table 2). In addition, because pneumothoraces
are known complications due to venous access and/or central venous
catheter placement,8 these were conservatively included as part of the
primary end point. The OPC was calculated based on published
complication rates in populations with PAH that included central
venous catheter systemic bloodstream infections (0.43-1.13 per 1,000
patients-days9,10), site infections (0.26-0.87 per 1,000 patient-days11,12),
and complications from catheter thrombosis, mechanical dysfunction, or
catheter dislocation in the general central venous catheter population
(0.36-0.51 per 1,000 patient-days8,13,14 ). The sum of the upper rates for
these three complications was used as the OPC (2.5 per 1,000 patient-
days). An independent Adverse Events Advisory Committee reviewed all
adverse events and deaths to determine their relatedness to the study
procedures or system components. Adverse Event Advisory Committee
structure and duties are shown in e-Tables 1 and 2.
The ancillary end points included changes from baseline in plasma
treprostinil levels, 6-min walk distance (6MWD), NYHA functional
class, quality of life (QoL), treatment satisfaction, and delivery-system
management time. QoL was assessed by using the Cambridge
Pulmonary Hypertension Outcome Review (CAMPHOR), a PAH-
speciﬁc questionnaire.15 Generic health status was assessed with the
European Quality of Life-5 Dimensions (EQ-5D) Summary Health
Score.16 Treatment satisfaction was assessed with the Functional
Assessment of Chronic Illness Therapy Treatment Satisfaction general
questionnaire (FACIT-TS-G).17 Delivery system management time[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
Figure 1 – Implantation location of the drug delivery system.was assessed before and after implantation by asking patients to estimate
how many hours per week were spent managing their delivery system,
including time spent in travel to and from, as well as in, the PAH clinic.
Study Procedures
Baseline assessment of plasma treprostinil, 6MWD, NYHA functional
class, QoL, and delivery system management time were performed, and
the system was implanted within 2 weeks of enrollment. Prior to
implantation ($ 1 day), the existing external central venous catheter
was removed and replaced with a temporary peripheral IV or a
peripherally inserted central catheter. Implantations were performed
by experienced operators (cardiologists, anesthesiologists, or
surgeons) following specialized training overseen by the study
sponsor. During system implantation, the investigational catheter
was introduced into the superior vena cava via a subclavian,
cephalic, jugular, or axillary puncture/cutdown and sutured to the
venotomy site using the anchoring sleeve. An incision was made to
create a pocket in the abdomen for pump placement, and the
catheter was tunneled under the skin between the venous access site
and the pump pocket, and connected to the infusion pump (Fig 1).
The implanted pump was then programmed to deliver a primingjournal.publications.chestnet.orgbolus followed by continuous infusion of treprostinil from the pump
reservoir through the implanted catheter, and the external IV
infusion pump was discontinued.
Patients were discharged from the hospital approximately 24 h after
surgery with their implantable pump programmed to deliver the
same dose of treprostinil as their external pump. One week after
surgery, safety assessments were performed, and blood samples were
collected to determine treprostinil concentrations. Adverse events,
NYHA functional class, 6MWD, QoL, delivery system management
time, pump reﬁll data (if necessary), and device interrogations were
assessed at 6 weeks’ and at 3, 6, and 12 months’ postimplantation.
The FACIT-TS-G treatment satisfaction survey was administered at
6 weeks and 6 months’ postimplantation.
The implanted pump was reﬁlled with treprostinil via percutaneous
needle access to the pump reservoir. Reﬁlls occurred when the drug
volume in the pump reservoir was low at an interval dependent on
patient dose (up to 12 weeks). At the time of a reﬁll, any drug
remaining in the pump reservoir was removed and discarded, and
fresh drug was injected into the pump. Study procedures for the
reﬁlls of the fully implanted system were similar to those for
commercially available systems.18 The pump reﬁll process took
approximately 15 min when performed by a trained and experienced
clinician (typically a physician, physician’s assistant, or nurse).
Noncoring needles are used to pierce the self-sealing silicone septum
of the reservoir during the reﬁll process. The ﬂow rate was initially
programmed using the pump programmer to deliver the same dose
of treprostinil as delivered by the external pump, but it could be
adjusted up or down based on the clinical assessment of each patient.
Statistical Analysis
The number of patient-days contributed by each patient toward the
primary end point was obtained from the last date of known follow-
up minus the date of implantation. Sample size calculations were
performed based on the OPC determined from complication rates in
previous studies,8-14 and it was estimated that 22,000 days of follow-
up among 60 patients undergoing implantation would be required to
ensure 90% power. A one-sample exact test for the Poisson rate was
used to obtain the 97.5% one-sided upper conﬁdence bound of the
catheter-related complications. StatXact version 9 (Cytel, Inc) was
used to generate the Poisson rate CI.
Continuous variables are reported as the mean  SD, and a paired t
test was used to determine the signiﬁcance of changes in these
variables from preimplantation to postimplantation. For all analyses,
a P value <.05 was considered signiﬁcant.Results
Patients
Patients (n ¼ 64) were enrolled from June 2011 through
November 2012. Four patients were enrolled but did not
undergo implantation: two patients developed infections
from their external treprostinil delivery catheters
between enrollment and scheduled implantation, one
patient had insufﬁcient body size to accommodate the
implantable pump, and one patient was withdrawn due
to worsening PAH. All 60 procedures were successful,
and the mean follow-up time was 12.1  4.4 months.
Baseline demographic and clinical characteristics are
provided in Table 1.Treprostinil Dose
The mean dose of IV treprostinil at baseline was 71.4 
27.8 ng/kg/min, which is similar to previously reported
doses.19,20 The implantable pump can be programmed by
using telemetry for ﬂow rates of 0.048 to 24 mL/d. In the
present study, a treprostinil concentration of 10 mg/mL
was primarily used. The average reﬁll interval was
47.2 days (range, 19.5 to 94.3 days). The reﬁll interval was
dependent on body size, dose, treprostinil concentration,
low-reservoir alarm setting, and the pump reservoir size.
Primary End Point
The primary end point (catheter-related complications)
was assessed once all patients completed their 6-month29
TABLE 1 ] Baseline Patient Characteristics
Characteristic
Patients Undergoing
Implantation (N ¼ 60)
Age, y 50.1  13.5
Male sex 20%
Race/ethnic origin
Asian 3%
Black or African American 5%
Hispanic or Latino 13%
White or Caucasian 78%
Height, cm 165  11
Height, in 65  4.3
Weight, kg 75.6  16.9
Weight, lb 167  37
Classiﬁcation of PAH
Idiopathic 58%
Heritable 3%
Associated 38%
Preimplantation IV treprostinil
dose, ng/kg/min
71.4  27.8
Time on dose at implantation,
wk
71.9  96.7
NYHA functional class
I 17%
II 50%
III 33%
No. receiving SC treprostinil
switched to IV treprostinil
within 12 wk of
implantationa
11 patients (18%)
(on IV 41  12 days;
range, 30-71 days)
Data are presented as mean  SD unless otherwise indicated. NYHA ¼
New York Heart Association; PAH ¼ pulmonary arterial hypertension;
SC ¼ subcutaneous.
aAll patients met study inclusion criteria.follow-up visit and there were at least 22,000 patient-
days of follow-up. This criterion was met in June
2013 with a total of 22,013 patient-days accumulated.
Six catheter-related complications were observed in
ﬁve patients and included three catheter dislocations
(two patients), one episode of venous stenosis, one
episode of mechanical catheter damage, and one
episode of pneumothorax (Table 2). No catheter-related
bloodstream infections or occlusions occurred. The
complication rate was 0.27 per 1,000 patient-days, and
the 97.5% upper one-sided conﬁdence bound (0.59 per
1,000 patient-days) was signiﬁcantly less than the
OPC of 2.5 per 1,000 patient-days (P < .0001). In
addition, a post hoc analysis showed that the observed
complication rate (0.27 per 1,000 patient-days) was
signiﬁcantly less (P < .0001) than the sum of the three30 Original Researchlower rates reported in the literature (1.05 per
1,000 days).
Complications
All complications that were related to the catheter,
implant procedure, pump, and pump reﬁll process are
listed in Table 2. Some complications were adjudicated
by the Adverse Events Advisory Committee as related to
multiple system components and/or procedure steps,
and these are listed based on their primary relatedness.
Multiple associated complications during a single
hospitalization (eg, infection that led to sepsis and renal
failure) were counted as a single complication. There
were a total of 16 complications in 14 patients.
Three pump reﬁll-related complications were reported
in three patients; these were deﬁned as local and/or
systemic symptoms and adverse effects of treprostinil
delivery soon after an implanted pump reﬁll procedure
requiring an invasive intervention. Local adverse effects
included pain, erythema, and/or swelling near the pump
reﬁll site. Systemic symptoms included ﬂushing,
headache, nausea, and/or a decrease in blood pressure.
The rate of reﬁll-related complications (based on three
complications) was 0.7% per reﬁll and was attributed to
a small amount of drug exiting the needle as the needle
was withdrawn from the pump reservoir.
Deaths
Three deaths occurred among the 60 patients
undergoing implantation. None was adjudicated to be
related to the system, procedure, or treprostinil. One
patient experienced a fatal pulmonary thromboembolism
4 months’ postimplantation due to a leg injury in a
motor vehicle accident. A second patient died 3 months’
postimplantation after hospital admission for refractory
heart failure. The patient was treated with palliative
care, and all medications were discontinued, including
treprostinil. The third death occurred when the patient
was admitted to the hospital with severe gastrointestinal
bleeding and underwent hemoclipping of a Dieulafoy
lesion. The patient died 10 months’ postimplantation
of right-sided heart failure due to excessive ﬂuid
resuscitation.
Ancillary End Points
Plasma treprostinil levels at 1 week postimplantation
were highly correlated with baseline levels (r ¼ 0.91;
P < .0001) (Fig 2).
The QoL results are summarized in Table 3. CAMPHOR
scores of mean changes in the symptom scale and QoL[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
TABLE 2 ] Complications Related to the Procedure or System During 22,013 Patient-Days of Follow-up
Complication and Relatedness
No. of
Occurrences Comment
Implant procedure related
Atrial ﬁbrillation 1 Prior to catheter insertion
Resolved by cardioversion
Fever, unknown origin 1 Admitted for observation; negative culture results
Pump pocket infection 1 Resolved after surgical modiﬁcation and antibiotics
Legionella pneumonia with septic shock, renal
failure, and DVT at the PICC line site
1 Subject recovered after 34-day hospitalization
Urinary retention 1 Urinary catheterization required
Catheter related (primary end point)a
Catheter dislocations 3 Dislocated catheters removed and replaced via surgical
procedures
Venous stenosis 1 187 days’ postimplantation
Damaged catheter 1 Catheter migrated over the reﬁll port and was pierced
with the needle during reﬁll
Pneumothorax 1 Associated with subclavian venous access; required chest
tube; discharged 2 days; postimplantation
Pump-related
Pump pocket seroma 2 Fluid from pump pocket in 2 subjects aspirated at 13 and
70 days after implantation
Pump reﬁll process related
Reﬁll reactions 3 3 subjects treated due to local and/or systemic reaction
shortly after reﬁll
Programmer related 0
Total system-related complications 16
PICC ¼ peripherally inserted central catheter.
aSix catheter-related complications is a 0.27 per 1,000 patient-days complication rate (95% upper conﬁdence bound ¼ 0.59; P < .0001).scale from baseline to 6 months were not signiﬁcant
(P ¼ .41 and P ¼ .22, respectively); however, there was a
small signiﬁcant increase in the activity scale (P ¼ .02).0
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Figure 2 – Plasma treprostinil levels at baseline and 1 week post-
implantation (r ¼ 0.91; P < .0001).
journal.publications.chestnet.orgThe mean EQ-5D score did not change from baseline to
6 months (P ¼ .43). At 6 weeks, according to the
FACIT-TS-G, patients were satisﬁed with the therapy;
they had a mean treatment satisfaction score of 94.7
 13.9 and a mean recommendation score of 98.3  9.1
(of 100). Patients were asked, “How do you rate this
treatment overall?” All patients answered good, very
good, or excellent at both 6 weeks and 6 months (n ¼ 60
at 6 weeks; n ¼ 58 at 6 months). Furthermore, 79% felt
that the effectiveness of the treatment was better than
expected at 6 months.
Compared with baseline, the increase in 6MWD
at 6 months was 1.7  21.6% for 56 patients
with paired data (Table 3); this difference was
not signiﬁcant (P ¼ .56). Similarly, there was no
signiﬁcant change in NYHA functional class from
preimplantation to postimplantation (P ¼ 0.99).
The mean delivery system management time was
2.5  1.7 h per week preimplantation and decreased
signiﬁcantly (P < .0001) to 0.6  0.8 hour per week at
6 months.31
TABLE 3 ] Change in Efﬁcacy Variables Between Baseline and 6 Months’ Postimplantation
Variable
CAMPHOR (n ¼ 57)
EQ-5D
(n ¼ 58)
NYHA
(n ¼ 58)
6-Min Walk Distance
(% change)
(n ¼ 56)
Symptom
Scale
Activity
Scale
QoL
Scale
Change, mean  SD –0.4  3.5 1.0  3.1a –0.5  3.1 –0.01  0.10 0.00  0.56 1.7  21.6
95% CI –1.3 to 0.5 0.2 to 1.8 –1.3 to 0.3 –0.04 to 0.02 –0.15 to 0.15 –4.1 to 7.5
Change (at least 2 points)
Better 19 (33%) 10 (18%) 18 (32%) NA NA NA
No change 24 (42%) 26 (46%) 29 (51%)
Worse 14 (25%) 21 (37%) 10 (18%)
Higher CAMPHOR scores and lower EQ-5D scores indicate worse quality of life. CAMPHOR ¼ Cambridge Pulmonary Hypertension Outcome Review; EQ-5D ¼
European Quality of Life-5 Dimensions; NA ¼ not applicable. See Table 1 legend for expansion of other abbreviation.
aOnly the change in the activity scale was signiﬁcant (P ¼ .02).Discussion
This study describes a novel implantable treprostinil
delivery system to treat patients with PAH. Successful
implantation was achieved with minimal catheter-
related complications. The study patients showed no
change in 6MWD or NYHA functional class, which was
expected because treprostinil has been proven effective
in previous studies,19,20 and postimplantation dosing
was based on each patient’s clinical condition.
Furthermore, the target dose was achieved by the
implantable system, as plasma treprostinil levels at
1 week were highly correlated with baseline levels.
Patients were satisﬁedwith their implanted delivery system
at both 6 weeks and 6 months, as supported by ﬁndings
from the FACIT-TS-G treatment satisfaction survey.
Moreover, patients spent 75% less time managing their
delivery system (average of 0.6 hour per week) at 6 months
compared with the external system that they used prior to
implantation (average of 2.5 hours per week). The low
catheter complication rate, reduced delivery system
management time, and the high rate of patient satisfaction
in this study suggest that the implanted delivery system
may be an important new option for patients with PAH
who require parenteral treprostinil.
The observed catheter dislocations occurred within
1 month of implantation and resulted in complete
displacement of the catheter from the vasculature.
Dislocations were identiﬁed following patient
complaints of pain along the subcutaneous catheter
track and/or within the pump pocket, resulting from
local delivery of treprostinil. Detailed analysis revealed
that the dislocations likely occurred because of
inadequate compressive force exerted on the catheter by
the sutures tied on the anchoring sleeve. Additional
training was given to operators performing the32 Original Researchimplantations, and there were no further dislocations in
39 subsequent procedures.
Adverse events associated with the priming bolus
resulting in hypotension occurred when transitioning
patients from an external system to the implantable
delivery system. Hypotension and other systemic
adverse effects from excess treprostinil were observed
during delivery of a priming bolus into the implanted
catheter in three of the ﬁrst four procedures. Excess
dosing during the transition was remedied by reducing
the drug volume used to prime the implantable delivery
system, while extending the drug delivery time via the
external pump. With the 57 new procedures and three
system modiﬁcations performed with this revised
method, no episodes of hypotension were observed
during the priming bolus.
This study has important limitations. There was no
parallel control group with patients receiving treprostinil
through an external pump. Given the novel technology
evaluated, enrollment was limited to patients already
shown to tolerate systemic treprostinil and who were
receiving a stable dose. As such, the use of the delivery
system cannot be recommended during initial drug
titration in patients with PAH. In addition, patient size
and dosing must be considered to avoid the need for
excessively short reﬁll intervals.
Conclusions
The fully implantable programmable intravascular
delivery system delivered treprostinil to patients with
PAH, with a low rate of catheter-related complications
and a high rate of patient satisfaction. The use of this
system maintained NYHA functional class and 6MWD
but signiﬁcantly shortened the delivery system
management time.[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
Primary Study Results Addendum
At the end of the prespeciﬁed primary results analysis
period, all active study subjects continued to receive
treprostinil via the implanted delivery system. As part of
the clinical study, the amount of residual drug in the
pump reservoir was estimated by withdrawal into a
syringe prior to each reﬁll and recorded as the ratio of
that estimated residual volume to the amount that was
programmed to remain in the pump reservoir (ie, the
accuracy ratio). During the primary study period, the
accuracy ratio remained within prespeciﬁed boundaries
set based on earlier experience with the pump.
However, starting within 6 months after the primary
study period, it was observed that, over time, the
delivery system tended to deliver slightly less drug than
the programmed amount, and the decrease in deliveredjournal.publications.chestnet.orgdrug was related to the total volume of drug delivered
over the lifetime of the pump. This discrepancy is
attributable, in part, to an increased “back” pressure
from the investigational catheter (relative to catheters
used with the implanted pump in other applications
in which this discrepancy is not observed). No
adverse events reported to date have been attributed
to this observation, physicians continue to dose
treprostinil based on PAH symptoms, and no trend has
been identiﬁed between the apparent delivered dose
reduction and symptom-related changes in treprostinil
dose adjustments. Given these facts, the study Steering
Committee, the study Data Monitoring Committee, and
all study investigators have elected to continue the study
with ongoing review of the safety and accuracy of this
route of prostanoid delivery.Acknowledgments
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